Phaseline

Companies › Lantern Pharma

Lantern Pharma: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LP-300
Mesna analogue; protective agent against chemotherapy-induced toxicity
–Phase 2Adenocarcinoma of LungDec 2026
LP-284
Small molecule alkylating agent causing tumor cell death through DNA damage
–Phase 1Relapsed or Refractory LymphomasNov 2028
LP-184
Small molecule alkylating agent causing tumor cell death through DNA damage
–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05933265LP-184Phase 1Advanced Solid TumorOncologyJul 2026
NCT05456256LP-300Phase 2Adenocarcinoma of LungOncologyDec 2026
NCT06132503LP-284Phase 1Relapsed or Refractory LymphomasOncologyNov 2028

From the company's SEC filings

Cash and short-term investments of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 6 months at that burn, to Jan 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Neonc Technologies Bio-Path Holdings Inhibrx Biosciences Immuneering Oncolytics Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.